DVA vs ZYME · P/E 14, rev $12.82B vs rev $76.3M
DaVita HealthCare Partners Inc (DVA) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported DVA revenue for 2024-12-31 was $12.82B. Net income was $1.25B. Revenue was up 5.6% from 2023-12-31 to 2024-12-31. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
DVA currently screens at market cap $10.77B and trailing P/E 14.1. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the DVA and ZYME stock pages for the full models.
Not investment advice.